Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Combination of Eltrombopag With Immunosuppressive Therapy in East-Asian Patients With Severe Aplastic Anemia

Phase 2

Completed

Conditions: Severe Aplastic Anemia (SAA)

Interventions: Drug: eltrombopag
Drug: rabbit anti-thymocyte globulin (r-ATG)
Drug: cyclosporine A (CsA)

First Posted Date: 2020-03-31

Last Posted Date: 2025-03-03

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 36

Registration Number: NCT04328727

Locations: 🇨🇳
Novartis Investigative Site, Kaohsiung, Taiwan

Study of Capmatinib and Spartalizumab/Placebo in Advanced NSCLC Patients With MET Exon 14 Skipping Mutations

Phase 2

Terminated

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Drug: Spartalizumab
Drug: Capmatinib
Drug: spartalizumab placebo

First Posted Date: 2020-03-26

Last Posted Date: 2024-10-09

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 31

Registration Number: NCT04323436

Locations: 🇪🇸
Novartis Investigative Site, Valencia, Comunidad Valenciana, Spain
🇺🇸
Massachusetts General Hospital Liver and Kidney TX, Boston, Massachusetts, United States

Study to Assess Safety, Tolerability and Phamacokinetics of KAE609 Administered Intravenously in Healthy Subjects

Phase 1

Completed

Conditions: Malaria

Interventions: Drug: KAE609
Drug: Placebo

First Posted Date: 2020-03-25

Last Posted Date: 2021-12-13

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 57

Registration Number: NCT04321252

Locations: 🇧🇪
Novartis Investigative Site, Antwerpen, Belgium

BCMA-directed CAR-T Cell Therapy in Adult Patients With Multiple Myeloma

Phase 1

Terminated

Conditions: Multiple Myeloma

Interventions: Biological: PHE885

First Posted Date: 2020-03-23

Last Posted Date: 2025-05-20

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 96

Registration Number: NCT04318327

Locations: 🇺🇸
Uni of Chi Medi Ctr Hema and Onco, Chicago, Illinois, United States
🇺🇸
Beth Israel Deaconess Medical Cente, Boston, Massachusetts, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

and more 2 locations

Pharmacokinetics, Safety, Tolerability and Efficacy of a New Artemether-lumefantrine Dispersible Tablet in Infants and Neonates <5 kg Body Weight With Acute Uncomplicated Plasmodium Falciparum Malaria

Phase 2

Terminated

Conditions: Plasmodium Falciparum Malaria

First Posted Date: 2020-03-09

Last Posted Date: 2025-05-16

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 28

Registration Number: NCT04300309

Locations: 🇨🇩
Novartis Investigative Site, Kisantu, Bas Kongo, Congo, The Democratic Republic of the

PoC Study to Evaluate the Efficacy and Safety of Secukinumab 300 mg in Patients With Lichen Planus

Phase 2

Completed

Conditions: Lichen Planus: Cutaneous Lichen Planus, Mucosal Lichen Planus and Lichen Planopilaris

Interventions: Drug: secukinumab 300 mg Q2W
Drug: secukinumab 300 mg Q4W
Other: Placebo

First Posted Date: 2020-03-09

Last Posted Date: 2023-08-22

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 111

Registration Number: NCT04300296

Locations: 🇩🇪
Novartis Investigative Site, Wuerzburg, Germany

A Study of Select Drug Combinations in Adult Patients With Advanced/Metastatic BRAF V600 Colorectal Cancer

Phase 1

Terminated

Conditions: BRAF V600 Colorectal Cancer

Interventions: Drug: Dabrafenib
Drug: LTT462
Drug: LXH254
Drug: TNO155
Drug: Trametinib
Biological: Spartalizumab
Biological: Tislelizumab

First Posted Date: 2020-03-03

Last Posted Date: 2024-11-14

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 122

Registration Number: NCT04294160

Locations: 🇺🇸
University of California LA Santa Monica Location, Los Angeles, California, United States
🇺🇸
Massachusetts General Hospital Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Sarah Cannon Research Institute SC, Nashville, Tennessee, United States

and more 2 locations

Retrospective Chart Review Study of Patients With PIK3CA-Related Overgrowth Spectrum Who Have Received Alpelisib

Completed

Conditions: PIK3CA-Related Overgrowth Spectrum (PROS)

Interventions: Other: alpelisib

First Posted Date: 2020-02-26

Last Posted Date: 2023-02-09

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 57

Registration Number: NCT04285723

Locations: 🇪🇸
Novartis Investigative Site, Madrid, Spain
🇺🇸
Boston Childrens Hospital, Boston, Massachusetts, United States

Study of Select Combinations in Adults With Myelofibrosis

Phase 1

Withdrawn

Conditions: Primary Myelofibrosis
Myelofibrosis
PMF
Post-Essential Thrombocythemia Myelofibrosis
Post-Polycythemia Vera Myelofibrosis

Interventions: Drug: MBG453
Drug: NIS793
Drug: Decitabine
Drug: Spartalizumab

First Posted Date: 2020-02-25

Last Posted Date: 2021-03-04

Lead Sponsor: Novartis Pharmaceuticals

Registration Number: NCT04283526

Study of Efficacy and Safety of Brolucizumab Versus Panretinal Photocoagulation Laser in Patients With Proliferative Diabetic Retinopathy

Phase 3

Completed

Conditions: Proliferative Diabetic Retinopathy

Interventions: Procedure: Panretinal photocoagulation laser
Biological: Brolucizumab 6 mg

First Posted Date: 2020-02-20

Last Posted Date: 2025-03-14

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 689

Registration Number: NCT04278417

Locations: 🇺🇸
Retina- Vitreous Assoc Medical Group ., Beverly Hills, California, United States
🇺🇸
Retina Associates SW, Tucson, Arizona, United States
🇺🇸
Retina Consultants of Orange County, Fullerton, California, United States

and more 30 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy